Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 6/20 | 0.65 |
| ▸ | BRD4 | O60885 | 6/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19484524 | 0.79 | CREBBP (1.00) | CREBBPBRD4ADORA1ADORA3 | |
| SCHEMBL19484522 | 0.77 | CREBBP (1.00) | CREBBPBRD4ADORA1ADORA3 | |
| SCHEMBL10345022 | 0.76 | HSD17B10 (0.54) | ADORA2AADORA3 | |
| SCHEMBL19490135 | 0.75 | CREBBP (0.90) | CREBBPBRD4ADORA1ADORA3 | |
| SCHEMBL15551492 | 0.69 | BRD4 (0.54) | CREBBPBRD4ADORA1ADORA2AADORA2B | |
| SCHEMBL19460469 | 0.68 | BRD4 (0.40) | CREBBPBRD4ADORA1ADORA2AADORA2B | |
| SCHEMBL7711745 | 0.68 | HSD17B10 (0.54) | ADORA2AADORA3ALOX5APFEN1 | |
| SCHEMBL3706777 | 0.67 | BRD4 (0.43) | CREBBPBRD4ADORA1ADORA2AADORA2B | |
| SCHEMBL27702335 | 0.67 | BACE1 (0.49) | ADORA1ALOX5APFEN1 | |
| SCHEMBL23066466 | 0.67 | ALDH1A1 (0.61) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | CREBBP 32/4885BRD4 5/4885ADORA1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.